With over 25 years of experience in the pharmaceutical and radiopharmaceutical industry, Mark Moran has held senior leadership roles across clinical, manufacturing, and commercial domains. He has played a pivotal role in bringing innovative diagnostic and therapeutic radiopharmaceuticals to market in the UK, including first clinical doses of Ga-68 and Lu-177 compounds for neuroendocrine and prostate cancers. Mark has led GMP site operations, driven licensing and market access strategies, and worked closely with the NHS, procurement hubs, NICE, and advocacy groups to expand patient access. Now through Avanovi Medical Ltd, he offers expert consulting services to companies navigating the complex radiopharmaceutical landscape.More...